Physician profile
Iris Zink
NPI 1487729752
$36,711.54
in general payments reported to CMS, 2019-2025
43 companies · $7,094 in 2025
The $7,094 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $4,908 · 2023: $5,755 · 2024: $6,913 · 2025: $7,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $3,990 · Education: $242 · Travel and Lodging: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,301.50 |
| Consulting Fee | $3,990.00 |
| Education | $242.12 |
| Travel and Lodging | $227.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $8,907.41 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $5,105.83 | 2021-2025 | Cimzia, Bimzelx, Briviact |
| Abbvie INC. | $4,928.56 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $4,814.03 | 2021-2025 | Orencia, Sotyktu |
| Amgen INC. | $3,311.66 | 2021-2025 | Tavneos, Enbrel, Amjevita |
| Horizon Therapeutics Plc | $1,332.65 | 2021-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $1,309.30 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $1,272.80 | 2021-2025 | |
| Lilly USA, LLC | $868.60 | 2021-2024 | Taltz |
| Pfizer INC. | $493.71 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.46 | 2021-2025 | Ofev, Cyltezo |
| Glaxosmithkline, LLC. | $381.74 | 2021-2023 | Benlysta |
| Organon LLC | $364.84 | 2023-2025 | Hadlima, Renflexis |
| Ani Pharmaceuticals, INC. | $321.51 | 2023-2025 | Purified Cortrophin Gel |
| Janssen Scientific Affairs, LLC | $290.20 | 2021-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $270.49 | 2023-2025 | Idacio |
| Alexion Pharmaceuticals, INC. | $254.50 | 2021-2025 | Strensiq |
| Genzyme Corporation | $214.17 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $210.51 | 2021-2023 | Lupkynis |
| Alvogen INC | $202.85 | 2022-2025 | Teriparatide |
| Sobi, INC | $201.30 | 2021-2025 | |
| Genentech USA, INC. | $200.13 | 2021-2025 | Gazyva, Actemra |
| Radius Health, INC. | $190.82 | 2021-2025 | Tymlos |
| Leo Pharma INC. | $122.34 | 2025 | Anzupgo |
| Ferring Pharmaceuticals INC. | $107.38 | 2021-2023 | Euflexxa |
| Sandoz INC. | $88.72 | 2023-2025 | Hyrimoz, Jubbonti |
| Daiichi Sankyo INC. | $80.06 | 2021-2023 | Injectafer |
| Boston Scientific Corporation | $48.75 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $47.05 | 2023 | Acthar |
| Fidia Pharma USA INC. | $43.69 | 2022-2024 | Hymovis |
| Actelion Pharmaceuticals US, INC. | $41.71 | 2023-2024 | Opsumit, Uptravi |
| Mylan Institutional INC. | $36.19 | 2023 | Hulio |
| Biocon Biologics INC | $34.34 | 2023-2024 | Hulio |
| Biohaven Pharmaceuticals, INC. | $32.67 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.66 | 2022 | |
| Kyowa Kirin, INC. | $22.19 | 2025 | |
| Lundbeck LLC | $20.78 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.99 | 2021 | |
| Bioventus LLC | $17.75 | 2023 | Supartz Fx Sodium Hyaluronate |
| Takeda Pharmaceuticals U.S.A., INC. | $15.78 | 2023 | Hyqvia |
| Krystal Biotech INC | $15.61 | 2024 | Vyjuvek |
| Antares Pharma, INC. | $14.38 | 2021 | |
| Ibsa Pharma INC. | $13.43 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Zink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.